Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report specifically addresses the notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
On October 12, 2010, administrators notified the company of an increase in interests in Ordinary share ADRs for specific individuals following the reinvestment of dividends paid on October 7, 2010. The transaction price was $41.19 per ADR.
- Mr. E J Gray: Increase of 14.63 ADRs.
- Mr. D J Phelan: Increase of 443.50 ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of ADRs held by Mr. E J Gray and Mr. D J Phelan post-transaction.
- Confirm the dividend reinvestment terms for the SmithKline Beecham Mid-Term Incentive Plan.
- Check subsequent filings for any further director transactions or changes in beneficial ownership.